Gagelman et al. evaluated 240 patients with CMML with a median follow-up of 5.5 years and proposed a prognostic system (named CMML transplant score) that accounts for ASXL1 and/or NRAS mutations (four points), a percentage of BM blasts > 2% (four points), and a comorbidity index (one point for eight different comorbidities), which cumulates in five risk groups with significant differences in survival and non-relapse mortality [133]. The gene discussed is NRAS; the disease is chronic myelomonocytic leukemia.